chronic myeloid leukemia

ENGAGING EXPERTS

Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy

01/14/2021

Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.

Ehab Atallah, MD, discusses...

01/14/2021

Journal of Clinical Pathways

News

TKI Discontinuation Associated With Improved PROs in CML

12/03/2020

Journal of Clinical Pathways

Research in Review

Dose Escalation of CML Treatment Improves Molecular Response Rates

08/02/2017

JCP Editors

Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...

...

08/02/2017

Journal of Clinical Pathways

Research in Review

CML Treatment Decisions Should Factor in Cardiovascular Disease Risk

07/27/2017

JCP Editors

Cardiovascular disease rates and its associated risks are increased in patients with chronic myelogenous leukemia (CML) treated by community-based oncologists and should impact treatment decisions, according to a...

...

07/27/2017

Journal of Clinical Pathways

Research in Review

Second TKI Discontinuation Attempt Safe in Patients With CML

07/27/2017

JCP Editors

Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...

...

07/27/2017

Journal of Clinical Pathways

Research in Review

Decreasing TKI Dosage Provides Better Outcomes in CML, Lowers Costs

06/29/2017

JCP Editors

Patients with chronic myeloid leukemia (CML) who receive half the standard dose of tyrosine kinase inhibitor (TKI) therapy are likely to eliminate most adverse events, drastically reduce costs, and improve...

...

06/29/2017

Journal of Clinical Pathways

Research in Review

TKI Safe and Effective in Pediatric CML

06/15/2017

JCP Editors

A recent study demonstrated high response rates and tolerable safety profiles in pediatric patients with chronic myeloid leukemia (CML) after treatment with a tyrosine kinase inhibitor (TKI). ----- Related...

A...

06/15/2017

Journal of Clinical Pathways

Research in Review

TKI Discontinuation Improves Remission Rates for Patients With CML

03/03/2017

JCP Editors

Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...

...

03/03/2017

Journal of Clinical Pathways

Research in Review

Combining Targeted Therapies Provides Optimal Treatment for CML

11/17/2016

JCP Editors

Using mathematical modeling, researchers have determined the best combination and sequencing of targeted therapies for the treatment of chronic myeloid leukemia (CML). Their results have been published in PLOS...

Using...

11/17/2016

Journal of Clinical Pathways

From the Field

Mock Clinical Pathways: A Method for Exploring the Oncology Clinical Pathway Development Process

05/06/2016

Bruce Feinberg, DO

Monica Lingam, MS

Bing-E Xu, PhD

Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...

...

05/06/2016

Journal of Clinical Pathways